chansin
暂无个人介绍
IP属地：未知
385关注
14粉丝
0主题
0勋章
5 Tech Stocks Seeing Massive Insider Buying
Skillz to Participate in RBC Capital Markets Technology, Internet, Media and Telecom ConferenceWed, November 10, 2021, 5:15 AM · 1 min readIn this article:
Sorrento Awarded California Competes Tax CreditSorrento Therapeutics, Inc.Mon, November 8, 2021, 2:08 AM · 4 min read
Nano Dimension Announces New DragonFly IV 3D-Printer and FLIGHT Software Package.Nano Dimension Ltd.Mon, November 8, 2021, 9:00 PM · 5 min readIn this article:
Nano Dimension Acquires Essemtec AG, Surface-Mount Pick & Place Systems Supplier for the PCB and OEM IndustriesGlobeNewswire2021-11-03 13:00Nano Dimension+0.86%Post
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age
@me168:$Histogenics(OCGN)$https://youtu.be/TUMlkkCBPfY start listening from 2h18min mark. Let Dr Fauci answer our doubts
Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced today that it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of Ocugen’s COVID-19 vaccine candidate BBV152, known as COVAXIN™ outside of the U.S., for pediatric use. The vaccine candidate was developed by the company’s partner, Bharat Biotech, and was studied in an immuno-bridging clinical trial conducted in India with children 2-18 years of age
@Yanningxd:$Histogenics(OCGN)$BWAHAHAHAHA cover this shorties
Like
@孟浩:摩根大通推荐了12只东南亚股票，你最看好谁？
Once Taboo, SPACs Are Now the Main Driver of Fundraising and New Growth in CannabisStreetInsider2021-11-02 08:08
BRIEF-Aldeyra Therapeutics Announces Achievement Of Primary Endpoint Of Ocular Redness In Mid-Stage Study In Dry Eye DiseaseReuters2021-11-02 20:06Aldeyra Therapeutics-7.47%
LiveOne Announces Record 6-Month Revenue of $60.7 Million, Up 142%, and Second Quarter Revenue of $21.9 Million, Up 51%Fri, October 29, 2021, 4:05 AM · 20 min readIn this article:
Selecta Biosciences and Ginkgo Bioworks Announce Partnership to Advance Treatments for Orphan and Rare DiseasesSelecta Biosciences, Inc.October 26, 2021 · 7 min read
Huawei’s HarmonyOS Ecosystem Integrates LIZHI PodcastLIZHI INC.October 25, 2021 · 5 min readIn this article:
Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature MedicineOctober 11, 2021 · 7 min readIn this article:
Gevo Stock Looks Like It's Ready To Break Out Of A Pennant PatternTyler BundyTue, October 26, 2021, 1:31 AM · 1 min readIn this article:
UP Fintech Holding Limited’s Singapore Subsidiary Receives Approval Regarding CDP Depository Agent in SingaporeOctober 28, 2021 4:00 AM
FuelCell, Nike, SoFi Stocks Prepare For Breakouts In This Bullish PatternMelanie SchafferOctober 21, 2021 · 2 min read
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical StudiesVYNE Therapeutics Inc.Tue, October 26, 2021, 8:00 PM · 8 min readIn this article:
Lead BET Inhibitor, VYN201, Significantly Reduces Expression of Several Key Pro-Inflammatory Cytokines in Preclinical StudiesVYNE Therapeutics Inc.Tue, October 26, 2021, 8:00 PM · 8 min readIn this article:
抱歉，原内容已删除
The Daily Biotech Pulse: Novavax Retreats Amid Vaccine Issues, LumiraDx COVID Test Approved In India, Sesen Shines On Positive Bladder Cancer ReviewBenzinga2021-10-20 20:16
去老虎APP查看更多动态